The observational study aimed at evaluating the incidence of systemic mastocytosis associated with t(8;21) AML in patients with de novo t(8;21) AML and their responses to first induction, and the prognosis from standard therapy.
This is a multicenter, retrospective and prospective, observational study that aims to collect clinical information on patients with systemic mastocytosis associated with t(8;21) AML from September 2022 to August 2023. No intervention is expected. The purpose of this study is to identify and characterize the patients with systemic mastocytosis associated with t(8;21) AML, t(8;21) AML without systemic mastocytosis, and OSM (Oligo-mastocytic SM) with associated t(8;21) AML. In order to estimate the incidence of systemic mastocytosis associated with t(8;21) AML, a survey will be sent every month to all participating sites to collect the number of all diagnoses of systemic mastocytosis associated with t(8;21) AML, t(8;21) AML without systemic mastocytosis, and OSM with associated t(8;21) AML. All patients will be followed until August 2025 in order to have at least 2 years of observation.
Study Type
OBSERVATIONAL
Enrollment
200
The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology
Suzhou, Jiangsu, China
RECRUITINGIncidence of Systemic Mastocytosis associated with t(8;21) Acute Myeloid Leukemia
Evaluation of the incidence of systemic mastocytosis associated with t(8;21) AML in patients with de novo t(8;21) AML. The incidence of systemic mastocytosis associated with t(8;21) AML will be evaluated by means of the number of diagnosis of systemic mastocytosis associated with t(8;21) AML on the number of all diagnoses of de novo t(8;21) AML between September 2022 and August 2023.
Time frame: at 1 year
Hematological characteristics of all the t(8;21) Acute Myeloid Leukemia
1. The neutrophils, eosinophils, basophils, and mast cells in WBC classification (%); 2. The proliferative degree in sections of BM (%); 3. The ratio of mast cells in BM smear and FCM (%); 4. The ratio of expression of CD25, CD2, and CD30 in FCM (%); 5. The quantification of the AML1-ETO gene fusions (%).
Time frame: at 1 year
Responses to the first induction therapy of all the t(8;21) Acute Myeloid Leukemia
1. The rate of eligible complete remission (CR) patients(%); 2. The rate of eligible CR with incomplete hematologic recovery (CRi) patients(%); 3. The rate of eligible morphologic leukemia-free state (MLFS) patients(%); 4. The rate of eligible partial remission (PR) patients(%); 5. The rate of eligible no response (NR) patients(%); 6. The rate of eligible CR without MRD patients(%); 7. The rate of eligible overall response rate (ORR) patients(%).
Time frame: at 1 year
Incidence of transplantation of all the t(8;21) Acute Myeloid Leukemia
The outcome of transplant in three groups of patients with systemic mastocytosis associated with t(8;21) AML, t(8;21) AML without systemic mastocytosis, and OSM with associated t(8;21) AML.
Time frame: at 1 year
Survival Distribution of all the t(8;21) Acute Myeloid Leukemia
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
1. Overall survival (months): Measured the time from enrollment to the date of the last follow-up or death; 2. Leukemia-free survival (months): Measured the time from the date of attaining CR1 until the first relapse, death, or the final follow-up day.
Time frame: at 2 years